Boston Scientific Subsidiaries Barred From Selling Multiple Drug-Eluting Stent Lines In Germany
This article was originally published in The Gray Sheet
Executive Summary
A German court had previously blocked Boston Scientific’s German subsidiary from selling drug-eluting stents affected by OrbusNeich’s patent suit; the new injunction closes a loophole, preventing any Boston Scientific subsidiary from selling the devices in Germany.
You may also be interested in...
News In Brief
Maquet acquires LAAx. OrbusNeich says it called the cops on Boston Scientific. More news
News In Brief
Two deputy commissioners depart FDA. NICE takes over U.K. program to encourage adoption of new medical technologies. More news.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.